Cyclopentamine is a sympathomimetic alkylamine, classified as a vasoconstrictor. Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia. It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Torasemide | The risk or severity of adverse effects can be increased when Torasemide is combined with Cyclopentamine. |
| Methyclothiazide | The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclopentamine. |
| Sulfisoxazole | The risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Cyclopentamine. |
| Chlorthalidone | The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cyclopentamine. |
| Ethoxzolamide | The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Cyclopentamine. |
| Sulfadiazine | The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Cyclopentamine. |
| Bendroflumethiazide | The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclopentamine. |
| Celecoxib | The risk or severity of adverse effects can be increased when Celecoxib is combined with Cyclopentamine. |
| Metolazone | The risk or severity of adverse effects can be increased when Metolazone is combined with Cyclopentamine. |
| Bosentan | The risk or severity of adverse effects can be increased when Bosentan is combined with Cyclopentamine. |
| Benzthiazide | The risk or severity of adverse effects can be increased when Benzthiazide is combined with Cyclopentamine. |
| Sulfamethizole | The risk or severity of adverse effects can be increased when Sulfamethizole is combined with Cyclopentamine. |
| Cyclothiazide | The risk or severity of adverse effects can be increased when Cyclothiazide is combined with Cyclopentamine. |
| Sulfametopyrazine | The risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Cyclopentamine. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclopentamine. |
| Furosemide | The risk or severity of adverse effects can be increased when Furosemide is combined with Cyclopentamine. |
| Tamsulosin | The risk or severity of adverse effects can be increased when Tamsulosin is combined with Cyclopentamine. |
| Hydroflumethiazide | The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cyclopentamine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cyclopentamine. |
| Indapamide | The risk or severity of adverse effects can be increased when Indapamide is combined with Cyclopentamine. |
| Acetazolamide | The risk or severity of adverse effects can be increased when Acetazolamide is combined with Cyclopentamine. |
| Chlorothiazide | The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclopentamine. |
| Bumetanide | The risk or severity of adverse effects can be increased when Bumetanide is combined with Cyclopentamine. |
| Sulfapyridine | The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Cyclopentamine. |
| Zonisamide | The risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclopentamine. |
| Hydrochlorothiazide | The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclopentamine. |
| Sulfamethoxazole | The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Cyclopentamine. |
| Trichlormethiazide | The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclopentamine. |
| Probenecid | The risk or severity of adverse effects can be increased when Probenecid is combined with Cyclopentamine. |
| Rosuvastatin | The risk or severity of adverse effects can be increased when Rosuvastatin is combined with Cyclopentamine. |
| Diazoxide | The risk or severity of adverse effects can be increased when Diazoxide is combined with Cyclopentamine. |
| Diclofenamide | The risk or severity of adverse effects can be increased when Diclofenamide is combined with Cyclopentamine. |
| Darunavir | The risk or severity of adverse effects can be increased when Darunavir is combined with Cyclopentamine. |
| Sulfacytine | The risk or severity of adverse effects can be increased when Sulfacytine is combined with Cyclopentamine. |
| Sulfadoxine | The risk or severity of adverse effects can be increased when Sulfadoxine is combined with Cyclopentamine. |
| Polythiazide | The risk or severity of adverse effects can be increased when Polythiazide is combined with Cyclopentamine. |
| Quinethazone | The risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclopentamine. |
| Glymidine | The risk or severity of adverse effects can be increased when Glymidine is combined with Cyclopentamine. |
| Sulfamerazine | The risk or severity of adverse effects can be increased when Sulfamerazine is combined with Cyclopentamine. |
| Sulfamethazine | The risk or severity of adverse effects can be increased when Sulfamethazine is combined with Cyclopentamine. |
| Piretanide | The risk or severity of adverse effects can be increased when Piretanide is combined with Cyclopentamine. |
| Hydroxyfasudil | The risk or severity of adverse effects can be increased when Hydroxyfasudil is combined with Cyclopentamine. |
| Sulfadimethoxine | The risk or severity of adverse effects can be increased when Sulfadimethoxine is combined with Cyclopentamine. |
| Simeprevir | The risk or severity of adverse effects can be increased when Simeprevir is combined with Cyclopentamine. |
| Sulfaphenazole | The risk or severity of adverse effects can be increased when Sulfaphenazole is combined with Cyclopentamine. |
| Sulfameter | The risk or severity of adverse effects can be increased when Sulfameter is combined with Cyclopentamine. |
| 5-(2-methylpiperazine-1-sulfonyl)isoquinoline | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclopentamine. |
| Fasudil | The risk or severity of adverse effects can be increased when Fasudil is combined with Cyclopentamine. |
| Sulfamoxole | The risk or severity of adverse effects can be increased when Sulfamoxole is combined with Cyclopentamine. |
| Vemurafenib | The risk or severity of adverse effects can be increased when Vemurafenib is combined with Cyclopentamine. |
| Azosemide | The risk or severity of adverse effects can be increased when Azosemide is combined with Cyclopentamine. |
| Clorsulon | The risk or severity of adverse effects can be increased when Clorsulon is combined with Cyclopentamine. |
| Sulfachlorpyridazine | The risk or severity of adverse effects can be increased when Sulfachlorpyridazine is combined with Cyclopentamine. |
| Sulfaethoxypyridazine | The risk or severity of adverse effects can be increased when Sulfaethoxypyridazine is combined with Cyclopentamine. |
| Sulfanitran | The risk or severity of adverse effects can be increased when Sulfanitran is combined with Cyclopentamine. |
| Sulfaquinoxaline | The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Cyclopentamine. |
| Setrobuvir | The risk or severity of adverse effects can be increased when Setrobuvir is combined with Cyclopentamine. |
| Chlorsulfaquinoxaline | The risk or severity of adverse effects can be increased when Chlorsulfaquinoxaline is combined with Cyclopentamine. |
| Sulfadicramide | The risk or severity of adverse effects can be increased when Sulfadicramide is combined with Cyclopentamine. |
| Phthalylsulfathiazole | The risk or severity of adverse effects can be increased when Phthalylsulfathiazole is combined with Cyclopentamine. |
| Sulfaisodimidine | The risk or severity of adverse effects can be increased when Sulfaisodimidine is combined with Cyclopentamine. |
| Meticrane | The risk or severity of adverse effects can be increased when Meticrane is combined with Cyclopentamine. |
| Sulfaperin | The risk or severity of adverse effects can be increased when Sulfaperin is combined with Cyclopentamine. |
| Mefruside | The risk or severity of adverse effects can be increased when Mefruside is combined with Cyclopentamine. |
| Mebutizide | The risk or severity of adverse effects can be increased when Mebutizide is combined with Cyclopentamine. |
| Sulfametomidine | The risk or severity of adverse effects can be increased when Sulfametomidine is combined with Cyclopentamine. |
| Cyclopenthiazide | The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Cyclopentamine. |
| Sulfatolamide | The risk or severity of adverse effects can be increased when Sulfatolamide is combined with Cyclopentamine. |
| Sulfamazone | The risk or severity of adverse effects can be increased when Sulfamazone is combined with Cyclopentamine. |
| Succinylsulfathiazole | The risk or severity of adverse effects can be increased when Succinylsulfathiazole is combined with Cyclopentamine. |
| Clorexolone | The risk or severity of adverse effects can be increased when Clorexolone is combined with Cyclopentamine. |
| Clofenamide | The risk or severity of adverse effects can be increased when Clofenamide is combined with Cyclopentamine. |
| Sulfathiourea | The risk or severity of adverse effects can be increased when Sulfathiourea is combined with Cyclopentamine. |
| Fenquizone | The risk or severity of adverse effects can be increased when Fenquizone is combined with Cyclopentamine. |
| Sulfaguanidine | The risk or severity of adverse effects can be increased when Sulfaguanidine is combined with Cyclopentamine. |
| Sulfamethoxypyridazine | The risk or severity of adverse effects can be increased when Sulfamethoxypyridazine is combined with Cyclopentamine. |
| Clopamide | The risk or severity of adverse effects can be increased when Clopamide is combined with Cyclopentamine. |
| Xipamide | The risk or severity of adverse effects can be increased when Xipamide is combined with Cyclopentamine. |
| Acetyl sulfisoxazole | The risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Cyclopentamine. |
| Methazolamide | The risk or severity of adverse effects can be increased when Methazolamide is combined with Cyclopentamine. |
| Indisulam | The risk or severity of adverse effects can be increased when Indisulam is combined with Cyclopentamine. |
| Buthiazide | The risk or severity of adverse effects can be increased when Buthiazide is combined with Cyclopentamine. |
| Sulfametrole | The risk or severity of adverse effects can be increased when Sulfametrole is combined with Cyclopentamine. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Botulinum toxin type B is combined with Cyclopentamine. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopentamine. |
| Cyclosporine | The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cyclopentamine. |
| Doxycycline | The risk or severity of adverse effects can be increased when Doxycycline is combined with Cyclopentamine. |
| Lymecycline | The risk or severity of adverse effects can be increased when Lymecycline is combined with Cyclopentamine. |
| Capreomycin | The risk or severity of adverse effects can be increased when Capreomycin is combined with Cyclopentamine. |
| Piperacillin | The risk or severity of adverse effects can be increased when Piperacillin is combined with Cyclopentamine. |
| Framycetin | The risk or severity of adverse effects can be increased when Framycetin is combined with Cyclopentamine. |
| Clomocycline | The risk or severity of adverse effects can be increased when Clomocycline is combined with Cyclopentamine. |
| Quinine | The risk or severity of adverse effects can be increased when Quinine is combined with Cyclopentamine. |
| Vancomycin | The risk or severity of adverse effects can be increased when Vancomycin is combined with Cyclopentamine. |
| Tigecycline | The risk or severity of adverse effects can be increased when Tigecycline is combined with Cyclopentamine. |
| Oxytetracycline | The risk or severity of adverse effects can be increased when Oxytetracycline is combined with Cyclopentamine. |
| Chloroquine | The risk or severity of adverse effects can be increased when Chloroquine is combined with Cyclopentamine. |
| Demeclocycline | The risk or severity of adverse effects can be increased when Demeclocycline is combined with Cyclopentamine. |
| Magnesium sulfate | The risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Cyclopentamine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Cyclopentamine. |